‘Glioblastoma broadband power as a longitudinal biomarker for tumor progression’

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON27265

Enrollment

100

Registered

2021-10-21

Start date

2021-10-01

Completion date

Unknown

Last updated

2024-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Glioblastoma (GBM)

Interventions

None

Eligibility

Inclusion criteria

Inclusion criteria: (1) age > 17 years (2) histopathologically confirmed GBM (3) eligible to start the standard treatment of concomitant chemoradiation followed by adjuvant chemotherapy

Exclusion criteria

Exclusion criteria: (1) psychiatric disease or symptoms at the time of inclusion (2) other comorbidities of the central nervous system, particularly cerebrovascular accidents, multiple sclerosis, Alzheimer’s disease at the time of inclusion (3) insufficient mastery of the Dutch language, (4) inability to communicate adequately. For undergoing the secondary endpoint of additional MRI measurement, patients are excluded when they have contraindications for MRI, but will still be included for the primary endpoints of MEG/EEG and tumor progression.

Design outcomes

Primary

Measure	Time frame
MEG peritumoral BB power, Radiological/Clinical progression	—

Secondary

Measure	Time frame
EEG peritumoral BB power, CEST MRI, rsfMRI, questionnaires	—

Contacts

Public ContactLinda Douw

AmsterdamUMC - locatie Vumc

l.douw@amsterdamumc.nl-

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)